Subscribe

Subscribe to Our Newsletter

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks
IO Biotech (IOBT) Receives 'Hold' Consensus from Analysts Amidst Clinical Development
clinical-trials Investment Trends biotech healthcare-funding

IO Biotech (IOBT) Receives 'Hold' Consensus from Analysts Amidst Clinical Development

Newsdesk profile image
by Newsdesk
Updated

AI-Generated Summary

IO Biotech (NASDAQ:IOBT) has garnered a consensus "Hold" recommendation from analysts, with an average 12-month price target of $8.00, according to MarketBeat. This analysis follows the clinical-stage biopharmaceutical company's recent earnings report and ongoing Phase 3 trials for its lead cancer vaccine candidate, IO102-IO103, reflecting market sentiment and institutional investment shifts.

In a nutshell

This report offers valuable market intelligence for healthcare investors and industry professionals monitoring biotech valuations. It underscores how analyst ratings and institutional activity are influenced by a company's clinical pipeline progress and financial performance.

Source: ETF Daily News

Newsdesk profile image
by Newsdesk
Updated

Be informed!

Rx.news delivers critical healthcare intelligence to pharmaceutical professionals, biotech innovators, healthcare investors, medical practitioners, and policy makers.

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Ok, Thanks

Read More